Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
STRS Stratus Properties Inc
ESMC Escalon Medical Corp
ATO Atmos Energy Corp
LVS Las Vegas Sands Corp
HUBB Hubbell Inc
PM Philip Morris International Inc
TSP TuSimple Holdings Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$118.25
Day's Change
0.18 (0.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
122.58
Day's Low
118.08
Volume
(Light)
Volume:
3,856,002

10-day average volume:
5,307,169
3,856,002

Display:

Providers:

UpdateCancel
4 providers
September 30, 2022
Moderna Inc. Stock Rises Friday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) inched 0.15% higher to $118.25 Friday, on what proved to be an all-around poor trading session for the stock...(MarketWatch)

1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds

By Ciara Linnane U.K. is the only G-7 country with a smaller economy now than before the pandemic About half of the American public has heard little or nothing about the new COVID-19 bivalent booster, a new survey by the Kaiser Family...(MarketWatch)

September 29, 2022
Moderna Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) slid 3.34% to $118.07 Thursday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

September 28, 2022
Moderna Inc. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) sank 0.07% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for the stock...(MarketWatch)

Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions

By Ciara Linnane Cases are rising again in northern Europe and almost half of U.S. states The Canadian government announced Monday it will no longer require people to wear masks on planes to guard against COVID-19, the Associated...(MarketWatch)

September 27, 2022
Moderna Inc. Stock Outperforms Market On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) rallied 2.12% to $122.23 Tuesday, on what proved to be an all-around mixed trading session for the stock...(MarketWatch)

Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11

By Ciara Linnane Moderna wants adolescents and younger children to be eligible for its bivalent vaccine Pfizer and German partner BioNTech said Monday they're seeking Food and Drug Administration authorization for their...(MarketWatch)

September 26, 2022
Moderna Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) slid 3.19% to $119.69 Monday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

September 23, 2022
Moderna Inc. Stock Falls Friday, Still Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) dropped 0.55% to $123.64 Friday, on what proved to be an all-around dismal trading session for the stock...(MarketWatch)

Health official says updated COVID-19 boosters likely to be available in weeks for elementary school-age children

Jaimy Lee Plus, Moderna is 'eager' to sell its COVID-19 shot in China, and U.S. cases continue to decline. A Food and Drug Administration official said this week that updated COVID-19 boosters for 5- to 11-year-olds will be authorized...(MarketWatch)

September 22, 2022
Moderna Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) slipped 1.15% to $124.32 Thursday, on what proved to be an all-around grim trading session for the stock...(MarketWatch)

Moderna expects the shortage of its updated COVID-19 booster to soon be resolved

Jaimy Lee Moderna still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year. Moderna Inc. (MRNA) said Wednesday that it expects to resolve supply issues for its new COVID-19 booster "in the coming...(MarketWatch)

September 21, 2022
Moderna Inc. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) slipped 3.04% to $125.76 Wednesday, on what proved to be an all-around poor trading session for the stock...(MarketWatch)

September 20, 2022
Moderna Inc. Stock Rises Tuesday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) rallied 1.41% to $129.71 Tuesday, on what proved to be an all-around poor trading session for the stock market...(MarketWatch)

Health experts dismayed by President Biden's view that the pandemic is over: 'Hell no -- not even close'

By Ciara Linnane Bus transporting people to quarantine crashes in China; Munich kicks off Oktoberfest Health experts reacted with dismay Monday to President Joe Biden's assertion that the pandemic is over in an interview on "60...(MarketWatch)

September 19, 2022
Moderna Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) slipped 7.14% to $127.90 Monday, on what proved to be an all-around favorable trading session for the stock...(MarketWatch)

Stocks end choppy session with gains as investors await Fed decision

By Vivien Lou Chen and William Watts U.S. stocks found their footing in the final hour of trading on Monday, after flipping between gains and losses, as investors prepared for a Federal Reserve meeting that's expected to deliver another...(MarketWatch)

Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over

Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. fell 9.2%, Pfizer Inc. was down 1.7% and its German partner...(MarketWatch)

September 16, 2022
Moderna Inc. Stock Rises Friday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Moderna Inc. (MRNA) rose 1.38% to $137.74 Friday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead's Veklury for severe disease

By Ciara Linnane Novavax vaccine allowed for children in Israel and adolescents in Taiwan A flurry of regulatory announcements relating to COVID treatments, vaccines and boosters dominated headlines on the pandemic Friday, with Europe...(MarketWatch)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.